| Date | Title | Description |
| 12.03.2024 | Aileron Therapeutics Announces CEO Transition | - |
| 31.10.2023 | Aileron Therapeutics Acquires Lung Therapeutics | Aileron Therapeutics, Inc. (NASDAQ: ALRN) acquired Lung Therapeutics, Inc., an Austin, Texas-based biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no a... |
| 26.10.2022 | Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR Internat... | p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss)
Study showed greater degree and longer... |
| 30.09.2022 | Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Socie... | New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells
Encore presentation of data presented at Society for Investigative Dermatology in May 2022 shows: ALRN-6924 temporarily ... |
| 22.09.2022 | Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference | BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel ... |
| 06.09.2022 | Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference | BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that a pre-r... |
| 15.08.2022 | Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights | Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trial
Extended cash runway expected to support operations through end of 1Q... |
| 01.08.2022 | Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer | Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patient... |
| 08.07.2022 | Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 | BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel A... |
| 29.06.2022 | Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924... | Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bia... |
| 19.05.2022 | Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer | Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities
Trial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, ... |
| 17.05.2022 | Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference | BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Ai... |
| 13.05.2022 | Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 | BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will h... |
| 05.05.2022 | Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights | On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022
On track to initiate Phase 1b clinica... |
| 28.03.2022 | Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights | Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or chemotherapy Expected readouts for Phase 1b t... |
| 22.03.2022 | Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference | BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, announc... |
| 05.01.2022 | Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones | Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22
Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial... |
| 04.01.2022 | Aileron Therapeutics to Present at Upcoming Investor Conferences | BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel A... |
| 12.11.2021 | Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights | Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy
Updated planned NSCLC study data readouts include interim... |
| 07.10.2021 | Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity | -- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent
for patients with p53-mutated cancer undergoing chemotherapy --
-- Preclinical data demonstrated ALRN-6924’s activation of p21-induced cell cycle arres... |
| 30.09.2021 | Aileron Therapeutics : Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 | BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new... |
| 11.05.2021 | AILERON THERAPEUTICS, INC.
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update | Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out expected at end of 2021
--
ALRN-6924 is designe... |
| 24.03.2021 | AILERON THERAPEUTICS, INC.
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights | 2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients
--
Advancing selective chemoprotection via p53 biomarker strategy; 50%... |
| 04.03.2021 | Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference | WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 2021 H.C. Wainwright G... |
| 02.03.2021 | Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) | -- Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed --
-- Trial anticipated to begin in second quarter 2021 with initial data anticip... |
| 08.01.2021 | ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer | Immuno-oncology spinout from Biolojic Design created with $40M Series A financing from ATP
Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON and TEL AVIV, January 8, 2021/PR NEWSWIRE/ – ATP, a leading... |
| 20.06.2017 | Term Sheet — Tuesday, June 20 | “I GOT A FEELING I’M OFF SCRIPT”
NEW MONEY + NEW PRODUCT: Managed by Q, a New York City-based on-demand office services startup, has launched a marketplace for its office management products, offering self-service cleaning, plumbing, electr... |
| 05.06.2017 | Aileron Therapeutics files for a $69M IPO as new offerings heat up | Joseph Yanchik, Aerilon
Aileron Therapeutics has set out to raise $69 million in the latest biotech IPO to hit the street.
Their lead drug — ALRN-6924 — is focused on p53, a familiar and very frustrating target in the cancer R... |
| 31.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | $33 million in equity raised, closing out a $48 million Series E round
The funding will bring Aileron candidate ALRN-6924 – a drug that works to activate a solid tumor suppressor protein called p53 – to clinical trial. The company says its ... |
| 30.10.2014 | Aileron Therapeutics closes $33M to launch clinical trials for solid tumor drug | Three new investors are involved here – AJU IB Investment Co., and two undisclosed private investment groups. It’s also got further funding from Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Ve... |
| 29.10.2014 | Aileron Therapeutics Secures $33M in Series E |
CAMBRIDGE, MA, Clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today that it has secured $33 million.
>> Click here for more ... |
| 29.10.2014 | Aileron Therapeutics Secures Additional $33M in Series E Financing | Aileron Therapeutics, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company that is developing therapeutics based on its proprietary Stapled Peptide drug platform, secured $33m in an extension to its Series E equity financing... |
| 18.11.2013 | Big Pharma venture arms bet $30M more on Aileron’s ‘stapled peptide’ drugs | The company’s lead candidate, ALRN-5281, is a long-acting growth-hormone-releasing factor agonist that it’s developing for treatment of orphan endocrine disorders including adult growth hormone deficiency and HIV-associated lipodystrophy. T... |
| 18.11.2013 | Aileron Therapeutics Secures $30M in Series E Equity Financing | Aileron Therapeutics, a Cambridge, MA-based clinical stage biopharmaceutical company, secured $30m in Series E equity financing.
Backers included Apple Tree Partners, Roche Venture Fund, Novartis Venture Funds, Lilly Ventures, SR One and Ex... |
| 18.11.2013 | Aileron Therapeutics Secures $30M in Series E |
CAMBRIDGE, MA, Clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today that it has secured $30 million in Series E equity financing.
... |
| 14.01.2013 | Aileron Therapeutics Secures $12M Series D |
CAMBRIDGE, MA, Aileron Therapeutics, Inc. today announced that it secured the second tranche in its Series D financing, bringing the total round to $42 million.
>> Click here for more funding data on Aileron Therapeutics
>> ... |
| 14.01.2013 | Biopharma adds $12M to advance “stapled peptide” technology to clinical trials | Attempts to modulate intracellular processes have historically failed, the company says, because peptides are broken down into inactive fragments by circulating enzymes and filtered from the bloodstream. But the biotech company’s approach “... |
| 14.01.2013 | Aileron Therapeutics Raises $12M in Series D Financing | Aileron Therapeutics, Inc., a Cambridge, Massachusetts-based biopharmaceutical company developing and advancing an innovative class of drugs called Stapled Peptides, raised $12m as a second tranche of its Series D financing.
Backers include... |
| 07.07.2009 | New life-science fund launches, Midwest investment on the horizon | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 15.04.2008 | Aileron Raises $10 Million | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Cambridge-based biopharmaceutical company Aileron Therapeutics, which is developing peptide drugs for the treatment of cancer and other diseases, has raised $10 million in a p... |
| 07.06.2007 | Aileron Therapeutics pulls in $7M for peptide therapies | Aileron Therapeutics, a Cambridge, Mass., developer of peptide-based drugs for cancer, raised $7 million in a second funding round. The company is at work on a new class of “stapled” peptides, or protein fragments, that it says can penetrat... |
| - | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | Each week, many millions are invested into life sciences startups. There are so many that often, they get lost in the weeds. We’re keeping track for you – based on regulatory filings reported to the SEC. Here are the new funding notices fro... |
| - | Big Pharma venture arms bet $30M more on Aileron’s ‘stapled peptide’ drugs | Just 10 months after closing the second tranche of a $42 million financing round, a biopharma developing a class of drugs called stapled peptides has collected another $30 million to advance a cancer drug candidate to the clinic.
Aileron Th... |
| - | Biopharma adds $12M to advance “stapled peptide” technology to clinical trials | Biopharmaceutical company Aileron Therapeutics Inc. is ready to advance what it says is a new class of drugs called stapled peptides into clinical trials after boosting its series D round to $42 million.
The Cambridge, Massachusetts, compan... |
| - | Aileron Therapeutics closes $33M to launch clinical trials for solid tumor drug | A new class of cancer drugs called “stapled peptides” has attracted a nice chunk of venture dollars. Cambridge biotech Aileron Therapeutics – the prime player in this space – just secured $33 million in investment, bringing its total Series... |
| - | New life-science fund launches, Midwest investment on the horizon | BOSTON, Massachusetts — A new health-care venture fund will invest in sectors ranging from information technology to life-science based agriculture.
Boston’s Excel Venture Management has already made three deals from its $125 million Excel ... |
